Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Primary Objectives:
-To determine the MTD and recommended Phase 2 dose (RP2D) of ipatasertib in combination with definitive chemoradiation in locally advanced head and neck squamous cell carcinoma (HNSCC) based on dose-limiting toxicities (DLTs).
Secondary Objectives:
- To assess acute and late toxicities, based on CTCAE version 5.0. Toxicities occurring >90 days from the end of radiation therapy will be considered late toxicities.
- To assess long-term swallowing function, based on gastric tube dependency at 6 and 12 months that is different from baseline.
- To determine duration and completion rate of prescribed radiation and chemotherapy.
- To determine pharmacokinetic profile of ipatasertib in combination with cisplatin and radiation therapy, based on peak and trough blood levels in patients administered ipatasertib orally.
- To determine pharmacodynamic effects of ipatasertib at the MTD, based on pAKT, pS6 and pPRAS40 as markers of AKT pathway inhibition, and gamma-H2AX as a marker of radiosensitization.
- To observe and record anti-tumor activity (objective response rate by RECIST criteria, locoregional control, relapse-free survival, and overall survival) of the combination of ipatasertib, cisplatin, and radiation therapy in patients with HNSCC. Although the clinical benefit of this combination has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit, and thus the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability.
- To correlate efficacy outcomes with tumor genotype, based on whole exome sequencing of pre-treatment biopsy specimens.
Larynx
Chemotherapy single agent systemic
- Rutgers Cancer Institute of New Jersey
Inclusion Criteria
- Patients must have pathologically confirmed HNSCC (including tumors of the
oropharynx, hypopharynx, larynx, oral cavity, nasal cavity, maxillary and other
paranasal sinuses, and unknown primary of the head and neck), with measurable
disease as per RECIST 1.1
- Oropharyngeal and unknown primary squamous cell cancers must test for human
papilloma virus (HPV), for example by p16 immunohistochemistry (IHC), in situ
hybridization (ISH), or polymerase chain reaction (PCR). HPV testing is not required
for other HNSCC primary tumor sites
- For the dose escalation phase only (not the expansion phase), patients with
p16-positive tumors are eligible if clinical stage III (cT4 or cN3, M0)
according to the American Joint Committee on Cancer (AJCC)/TNM Staging System,
8th edition (Ed.)
- For both the dose escalation and expansion phases, patients with p16-negative
(or not tested) tumors are eligible if clinical stage III-IVB (locally advanced
but non-metastatic) according to the AJCC/TNM Staging System, 8th Ed.
- Must be candidate for concurrent, definitive cisplatin and radiation therapy as
judged by the treating physician
- Able to swallow tablets at the time of enrollment
- Age >= 18 years. Because no dosing or adverse event data are currently available on
the use of ipatasertib in combination with chemoradiation in patients < 18 years of
age, children are excluded from this study
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Life expectancy of greater than 3 months
- Absolute neutrophil count >= 1500/mcL
- Hemoglobin >= 9 g/dL
- Platelets >= 100,000/mcL
- Serum albumin >= 3 g/dL
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase
[SGPT]) =< 2.5 x institutional ULN / 2 x institutional ULN
- Alkaline phosphatase (ALP) =< 2.0 x institutional ULN
- Partial thromboplastin time (PTT) (or activated [a]PTT) and international normalized
ratio (INR) =< 1.5 institutional ULN (except for patients receiving anticoagulation
therapy)
- Creatinine clearance (CLcr) > 50 mL/min
- For this calculation, use the Cockroft-Gault formula
- Fasting glucose =< 150 mg/dL (8.3 mmol/L) and (when indicated) glycosylated
hemoglobin (HbA1c ) =< 7.5% (58 mmol/mol)
- Human immunodeficiency virus (HIV)-infected patients are eligible if on effective
anti-retroviral therapy with undetectable viral load within 6 months
- Patients with past hepatitis B virus (HBV) infection or resolved HBV infection
(defined as having a negative hepatitis B virus surface antigen [HBsAg] test and a
positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV
deoxyribonucleic acid [DNA] test) are eligible. Patients with chronic HBV infection
are eligible if the HBV viral load is undetectable on suppressive therapy, if
indicated. Patients undergoing current treatment with anti-viral therapy for HBV are
ineligible
- Patients with a history of hepatitis C virus (HCV) infection are eligible only if
polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA). Patients
with HCV infection who are currently on treatment are eligible if they have an
undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or treatment
does not have the potential to interfere with the safety or efficacy assessment of
the investigational regimen are eligible for this trial
- The effects of ipatasertib on the developing human fetus are unknown. For women of
childbearing potential: agreement to remain abstinent (refrain from heterosexual
intercourse) or use contraceptive methods with a failure rate of < 1% per year
during the treatment period and for at least 28 days after the last dose of
ipatasertib and agreement to refrain from donating eggs during this same period. For
men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
contraceptive measures, and agreement to refrain from donating sperm during the
treatment period and for 28 days after the last dose of ipatasertib
- Ability to understand and the willingness to sign a written informed consent
document
- For the expansion cohort only, patients must agree to undergo mandatory on-treatment
biopsies, and have tumors amenable to on-treatment biopsies. This is not applicable
to the dose escalation cohort where no on-treatment biopsies are obtained
Exclusion Criteria
- Primary tumor of nasopharynx, salivary, thyroid or parathyroid glands, or skin
- Distant metastases from the current HNSCC
- Prior treatment (e.g., chemotherapy, radiation, or definitive surgery) for the
current locally advanced HNSCC is not permitted. Biopsies, including those performed
under anesthesia, are not considered surgery. Patients who underwent prior
definitive surgery alone for an early stage (T1-2N0) HNSCC which has now recurred
with stage III-IVB disease at least 3 months after the initial surgery are eligible
- For patients with a prior history of another malignancy, no prior chemotherapy or
radiation may have been administered within 6 weeks prior to study entry. Among
patients who received prior radiation to the head and neck or adjacent anatomical
site for another malignancy, there may be no overlap with current area to be
irradiated
- Current use of any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical or
biologic composition to ipatasertib or other agents used in study
- Treatment with strong inhibitors or inducers of CYP3A4 or P-glycoprotein within 2
weeks or 5 drug-elimination half-lives, whichever is longer, prior to initiation of
study drug. Because the lists of these agents are constantly changing, it is
important to regularly consult a frequently-updated medical reference. As part of
the enrollment/informed consent procedures, the patient will be counseled on the
risk of interactions with other agents, and what to do if new medications need to be
prescribed or if the patient is considering a new over-the-counter medicine or
herbal product
- Patients with uncontrolled intercurrent illness, including active infection
- Pregnant women are excluded from this study because ipatasertib is an oral AKT
inhibitor with the potential for teratogenic or abortifacient effects. Because there
is an unknown but potential risk for adverse events in nursing infants secondary to
treatment of the mother with ipatasertib, breastfeeding should be discontinued if
the mother is treated with ipatasertib. These potential risks may also apply to
other agents used in this study
- Patients with type I or type II diabetes mellitus requiring insulin at study entry.
Patients with non-insulin dependent type II diabetes mellitus are eligible, as are
patients who are on a stable dose of oral diabetes medication >= 4 weeks prior to
initiation of study treatment. Patients with a history of diabetes mellitus, an
abnormal fasting glucose level, or other signs or symptoms indicating diabetes
mellitus, must meet the laboratory eligibility criteria for fasting blood glucose
and hemoglobin A1c
- History of or active inflammatory bowel disease (e.g., Crohn's disease and
ulcerative colitis) or active bowel inflammation (e.g., diverticulitis)
- History of malabsorption syndrome or other condition that would interfere with
enteral absorption or results in the inability or unwillingness to swallow pills
- Lung disease: pneumonitis, interstitial lung disease, idiopathic pulmonary fibrosis,
cystic fibrosis, aspergillosis, active tuberculosis, or history of opportunistic
infections (pneumocystis pneumonia or cytomegalovirus pneumonia)
- Known clinically significant history of liver disease consistent with Child Pugh
Class B or C, including active viral or other hepatitis (e.g., positive for
hepatitis B surface antigen [HBsAg] or hepatitis C virus [HCV] antibody at
screening), or cirrhosis.
- Grade >= 2 uncontrolled or untreated hypercholesterolemia (cholesterol > 300 mg/dL
or > 7.75 mmol/L) or hypertriglyceridemia (triglycerides > 300 mg/dL or > 3.42
mmol/L)
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.